Buy Divis Labs, target of Rs 1370: Hem Securities

Hem Securities has initiated a buy rating on Divi’s Laboratories with a target price of Rs 1370 in its research report.

“Being a pioneer in the API and CRAMS segment, Divi’s Laboratories has posted tremendous growth over the past few years. With the leadership in dextromethorphan, phenyleffrine, nabumetone and lopamidol, the com-pany is expected to witness surge in its business. Further, with almost completion of massive capex, the company is expected to continue to post excellent financial performance on the back of its successful entry into the high margin nutraceuticals segment. In wake of the growth of the phar-maceutical sector, Divi’s Laboratories Ltd seems to be extremely attrac-tive investment opportunity.”

“Presently, the stock is trading at Rs 1088.60 which is at 16.92 times to its earnings and 5.68 times to its book value of Rs 191.72. Since the stock offers good opportunity, we initiate a ‘BUY’ signal on the stock with a target price of Rs 1370 in medium to long term investment horizon ex-pecting an appreciation of about 26% from the current level of Rs 1088.60”, says Hem Securities’ report.

source: Moneycontrol

Tags: buy or sell divis lab, divis labs, hem securities, hot stocks, NSE Tips, share tips daily, stock market india

Similar Posts:

• Buy Dishman Pharma, target of Rs 230: Hem Securities
• Buy Colgate; target of Rs 740: Hem Securities
• Buy GSK Pharma, target of Rs 1340: Hem Securities
• Buy Aban Offshore, target of Rs 484: Hem Securities
• Buy Bharat Electronics, target Rs 1230: Hem Securities